Related Experiment Video
Updated: Jul 3, 2026
13:59
High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
Published on: August 18, 2023
[Trastuzumab and Fcgamma]
Hiroyasu Yamashiro1, Masakazu Toi
1Dept. of Surgery, Graduate School of Medicine, Kyoto University, Kyoro, Japan.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|July 18, 2008
Summary
Trastuzumab efficacy may vary due to Fcgamma receptor gene polymorphism in effector cells, impacting antibody-dependent cell-mediated cytotoxicity. Understanding these genetic differences is crucial for developing new therapeutic antibodies and predicting treatment outcomes.
Area of Science:
- Immunology
- Pharmacogenomics
- Oncology
Context:
- Trastuzumab is a monoclonal antibody targeting HER2, a key driver in certain cancers.
- Antibody-dependent cell-mediated cytotoxicity (ADCC) is a primary anti-tumor mechanism for Trastuzumab.
- Individual variations in immune effector cells, specifically Fcgamma receptors, can influence treatment response.
Purpose:
- To investigate the role of Fcgamma receptor gene polymorphism in modulating Trastuzumab's anti-tumor activity.
- To explore the correlation between Fcgamma receptor subtypes and ADCC levels.
- To determine the impact of genetic variations on Trastuzumab treatment efficacy.
Summary:
- Trastuzumab, a HER2-targeted antibody, relies on ADCC for its anti-cancer effects.
- Differences in Fcgamma receptor gene polymorphism among individuals affect their affinity for Trastuzumab's Fc region.
- These variations lead to altered ADCC activity, potentially explaining differing treatment efficacies.
Impact:
- Highlights the significance of Fcgamma receptor gene polymorphism in personalized cancer therapy.
- Informs strategies for developing novel therapeutic antibodies with improved efficacy prediction.
- Suggests a pharmacogenomic approach to optimize Trastuzumab treatment selection and outcomes.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.